THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Neil K. Warma, the Company's President and Chief Executive Officer, has been featured in The Burrill Report. The interview, titled "Funding a Personalized Immunotherapy for MS" was conducted by Daniel S. Levine, the publication's editor, and highlights Opexa's recent progress.
Help employers find you! Check out all the jobs and post your resume.
